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Background: Fibroblast growth factor (FGF)-19, an endocrine FGF protein mainly produced by the ileum, stimulates
metabolic activity and alleviates obesity. FGF19 modulates metabolism after either intravenous or
intracerebroventricular injection, and its receptor FGFR4 is present in the hypothalamus. This led to the question
whether blood-borne FGF19 crosses the blood-brain barrier (BBB) to exert its metabolic effects.
Methods: We determined the pharmacokinetics of FGF19 permeation from blood to brain in comparison with its
distribution in peripheral organs. Multiple-time regression analysis after intravenous bolus injection, in-situ brain
perfusion, and HPLC assays were performed.
Results: FGF19 was relatively stable in blood and in the brain compartment. Significant influx was seen in the
presence of excess unlabeled FGF19 in blood. This coincided with a slower decline of 125I-FGF19 in blood which
suggested there was decreased clearance or peripheral tissue uptake. In support of an altered pattern of peripheral
processing of 125I-FGF19 by excess unlabeled FGF19, the high influx to liver was significantly attenuated, whereas
the minimal renal uptake was linearly accelerated. In the present setting, we did not detect a saturable transport of
FGF19 across the BBB, as the entry rate of 125I-FGF19 was not altered by excess unlabeled FGF19 or its mouse
homologue FGF15 during in-situ brain perfusion.
Conclusion: FGF19 remained stable in the blood and brain compartments for up to 10 min. Its influx to the brain
was non-linear, non-saturable, and affected by its blood concentration and distribution in peripheral organs. Liver
showed a robust and specific uptake of FGF19 that could be inhibited by the presence of excess unlabeled FGF19,
whereas kidney clearance was dose-dependent.
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Mouse fibroblast growth factor (FGF)-15 and its human
ortholog FGF19 are endocrine hormones mainly pro-
duced by the ileum to inhibit bile acid synthesis and
regulate the metabolism of lipids and glucose [1,2]. A
beneficial role of these polypeptides in metabolic signal-
ing is suggested by the higher energy expenditure, re-
duced adiposity, and resistance to diet-induced obesity
of FGF19 transgenic mice [3]. Direct treatment of
animals with FGF19 by either intravenous or intra-
cerebroventricular injection also produces similar effects
of increased energy expenditure [4]. Brown adipose
tissue and liver are major mediators of FGF19 in the
periphery. FGF15 is expressed in the developing brain
but appears to be absent in adults [5]. It has been* Correspondence: weihong.pan@pbrc.edu
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reproduction in any medium, provided the orsuggested that FGF19 acts on the brain. FGF19 reduces
24 h food intake, body weight, and glucose intolerance
after intracerebroventricular injection, and FGF recep-
tors 1 and 4 are present in the hypothalamus of rats and
upregulated by high-fat diet [6]. FGFR4 is also present in
the medial habenular nucleus [7] adjacent to the pineal
gland, suggesting a potential role of FGF15/19 signaling
in pain processing, reproductive behavior, nutrition,
sleep-wake cycles, stress responses, and learning. Thus,
FGF15/19 from the periphery might have crossed the
blood–brain barrier (BBB) to exert metabolic effects in
adult animals.
It has been long debated whether ingestive and meta-
bolic peptides exert prominent CNS effects by acting
through circumventricular organs (CVOs). In contrast to
the vast exchange interface of the BBB, the CVOs serve
unique regulatory functions. However, there is an astro-
cytic barrier between the area postrema (a CVO) and
nucleus tractus solitarius (inside the BBB) [8], and aal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and the arcuate nucleus of the hypothalamus [9,10].
There are several ways by which peptides and small
proteins interact with the BBB. The mechanisms of BBB
permeation, either by specific saturable transport sys-
tems or passive diffusion, would affect strategies for drug
delivery as well as physiological consequences of neuro-
endocrine crosstalk [11,12]. Among the FGF family of
growth factors, basic FGF (FGF2) is transported across
the BBB by adsorptive transcytosis [13], whereas FGF21
crosses the BBB by simple diffusion without saturable
influx [14]. Most recently it was shown that circulating
FGF19 is associated with remission of diabetes after
Roux-en-Y gastric bypass surgery for obesity [15]. With
the renewed interest in FGF15/19 in feeding and meta-
bolic activities, we quantified its ability to enter the brain
from the periphery.
Materials and methods
Animals and chemicals
Three-month-old male CD1 mice were purchased from
Charles River Laboratories International (Wilmington,
MA, USA,) and maintained at the animal care facility
with food and water ad libitum in a 12 h light/12 h dark
lighting schedule. The mice were used following a
protocol approved by the Institutional Animal Care and
Use Committee.
Human recombinant FGF19 and mouse recombinant
FGF15 were purchased from Prospec (Ness Ziona,
Israel). Bovine serum albumin (BSA) and chloramine-T
reagents for radioactive labeling were obtained from Sigma
(St. Louis, MO, USA). Iodination of FGF19 with 125I
(PerkinElmer, Shelton, CT, USA) and BSA with 131I
(PerkinElmer) was achieved by the chloramine-T method.
The radioactively iodinated peptides were purified on a col-
umn of Sephadex G-10 (Sigma). Acid precipitation indi-
cated that 99.4% of the 125I in the purified labeled peptides
was incorporated to FGF19 (125I-FGF19), while the ratio
for 131I and BSA (131I-albumin) was 99.7%. The specific
activities of 125I-FGF19 and 131I-albumin were 1.23 ×
108 cpm/μg (2.05 MBq/μg) and 1.18 × 108 cpm/μg
(1.97 MBq/μg), respectively.
Test of stability of FGF19 in mouse
Reversed phase high performance liquid chromatography
(HPLC)
The stability of FGF19 in the brain and circulation at
10 min was determined in brain homogenate and serum
samples (n = 3). After anesthesia, each mouse received
an iv bolus injection of 100 μl lactated Ringer’s solution
containing radioactively labeled tracers (6.8 × 106 cpm,
or 0.113 MBq of 125I-FGF19 and 3.6 × 106 cpm, or
0.06 MBq of 131I-albumin) and 1% BSA. The mouse was
decapitated 10 min after injection. Blood was collectedfrom the right carotid artery into an ice-chilled tube
immediately before decapitation. The brain was quickly
removed and homogenized on ice in 1 ml cold phosphate-
buffered saline (PBS) in the presence of 2× Halt™ protease
inhibitor cocktail (Pierce, Rockford, IL, USA). For control
experiments, brain from individual naïve mice was homoge-
nized in PBS containing about 3,500 cpm (5.8 × 10-5 MBq)
of 125I-FGF19 and 6,000 cpm (0.0001 MBq) of 131I-albumin.
The amount of radioactivity was similar to that in the brain
10 min after iv injection. The homogenate was centrifuged
at 18,000 g at 4°C for 20 min. Supernatant from two brains
was combined and filtered through a 0.22 μm syringe filter
(Fisher Scientific, Pittsburgh, PA) for HPLC analysis. Blood
was kept at 4°C overnight before centrifugation at 1,000 g
at 4°C for 20 min to obtain serum. Supernatant (about
5,100 cpm, 8.5 × 10-5 MBq) and 18 μl of serum (about
7,800 cpm, 0.00013 MBq) were diluted separately with ad-
equate amounts of HPLC-grade water (Sigma) containing
0.1% trifluoroacetic acid (Applied Biosystems, Grand Island,
NY, USA) so that the final volume of each sample was
about 1 ml for loading onto the 1-ml sample loop of the
HPLC. Separation was achieved with a protein C4 column
(Vydac, Hesperia, CA, USA). The mobile phase (contain-
ing 0.1% trifluoroacetic acid) increased from 10% aceto-
nitrile (EMD Chemicals Inc, Gibbstown, NJ, USA) linearly
over 40 min with a flow rate of 1 ml/min. Forty fractions
were collected at a rate of 1 fraction/min. The radioactiv-
ity of each fraction was measured with a dual-channel
program in a Wallac 1470 Wizzard γ-counter. The result
was plotted as the radioactivity of each fraction vs time.
The fractions with the maximum cpm value of the peaks
on the graph were further examined by acid precipitation
for confirmation.
Acid precipitation
The brains and sera collected at 5, 10, and 20 min after iv
injection of 125I-FGF19 and 131I-albumin for the multiple-
time regression analysis (shown below) were used for acid
precipitation analysis. The brains were processed as men-
tioned above to obtain the supernatant. Serum was diluted
with adequate amounts of PBS containing 1% BSA before
acid precipitation. Equal volumes of 30% trichloroacetic
acid (3 parts 50% trichloroacetic acid in water + 2 parts
brine) was added to the sample and vortexed. After incu-
bation on ice, the mixture was centrifuged at 3,400 g at
4°C for 20 min. The supernatant and precipitate were sep-
arated and the radioactivity measured with a dual-channel
program γ-counter. Acid precipitability was defined as the
percent of radioactivity in the total precipitate.
Kinetics of FGF19 influx from blood to brain
The kinetics of FGF19 transferring from blood to brain
across the BBB was determined by multiple-time regression
analysis and in-situ brain perfusion [16] with modifications
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blood-to-brain transfer of 125I-FGF19 in the presence or
absence of excess unlabeled FGF19 or FGF15 were com-
pared with those of the vascular marker 131I-albumin.
Multiple-time regression analysis
Two groups of mice were studied simultaneously. One
group of mice (n = 8) received iv injection of 100 μl lac-
tated Ringer’s solution containing 4.3 × 106 cpm
(0.072 MBq) of 125I-FGF19, 2.5 × 106 cpm (0.042 MBq)
of 131I-albumin and 1% BSA at time 0. At 1, 3, 5, 7, 10,
13, 16 or 20 min (the experimental time) after injection,
one mouse per time point was decapitated to collect
brain. Blood was also collected from the right carotid ar-
tery immediately before decapitation to obtain serum.
To determine whether FGF19 transport across BBB is a
saturable process, a second group of mice (n = 8) was
treated the same as the first group except that the injec-
tion solution contained an additional 2 μg/mouse un-
labeled FGF19 (about 56-fold excess to 125I-FGF19).
Radioactivity in brain and 50 μl serum was measured
with a dual-channel program on the γ-counter. For com-
parison and measurement of peripheral tissue uptake,
liver and kidney were also sampled.
Based on the exponentially decreasing pattern of 125I
radioactivity in serum over experimental time resulting
from the decline of 125I-FGF19 in blood, the exposure
time τ was calculated as the integral of serum radioactiv-
ity from time 0 to experimental time t divided by the
serum radioactivity at experimental time t [18]. It re-
presents the theoretical time needed for the tissue to ac-
cumulate 125I radioactivity from blood to the level
measured at experimental time t under a hypothetical
condition in which serum radioactivity remains constant
at the same level as at experimental time t throughout
the experiment. The radioactivity in the tissue (cpm) was
normalized to its weight (g) and to the radioactivity in the
serum (cpm/μl), and thus expressed as the tissue/serum ra-
tio (μl/g). The linear regression correlation between the tis-
sue/serum ratio and the exposure time (for 125I-FGF19) or
the experimental time (for 131I-albumin) was determined
with GraphPad Prism software (San Diego, CA). The uni-
directional influx rate (Ki, μl/g-min) and the initial volume
of distribution (Vi, μl/g) were defined as the slope and the
Y-axis intercept from the regression line, respectively.
In-situ brain perfusion
To study the kinetics of FGF19 transport across BBB
without interference from peripheral factors in the circu-
lation, 3 groups of mice (n = 10 /group) were transcar-
dially perfused with oxygenated modified Krebs buffer
containing 125I-FGF19 and 131I-albumin (1000 cpm/μl,
1.67 × 10-5 MBq) for 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or
5 min (one mouse per time point). The perfusion ofradioisotopes was preceded by a 2-min pre-wash and
followed by a 1-min post-wash with the same oxygen-
ated modified Krebs buffer without radioactively labeled
tracers. The flow rate was 2 ml/min, and perfusion was
driven by a syringe perfusion pump. The descending
aorta was completely clamped by a hemostat through-
out the perfusion. Mice were decapitated immediately
at the end of the post-wash. The “hot only” control
group received only radioactively labeled tracers. To de-
termine whether FGF19 transport from blood to brain
is saturable, two additional groups of mice (n = 10/
group) were perfused in the presence of 50-fold excess
unlabeled FGF19 (0.38 μg/ml) and FGF15 (0.38 μg/ml),
respectively, in perfusion buffer with radioactively
labeled tracers. The recipe of the modified Krebs buffer
is (g/L): NaCl 7.19, KCl 0.3, CaCl2 0.28, NaHCO3
2.1, KH2PO4 0.16, MgCl2▪6H2O 0.37, D-glucose 0.99
(pH = 7.4) with 1% BSA. The brain was collected for
measurement of radioactivity in the γ-counter. The
radioactivity of the tissue (cpm) was normalized to its
weight (g) and the radioactivity of the radioactively
labeled tracers (cpm/μl); the result was expressed as
tissue/perfusate ratio (μl/g). The brain/perfusate ratio of
125I-FGF19 was further normalized to that of 131I-albu-
min by subtraction. The linear regression correlation
analysis between normalized brain/perfusate ratio and
experimental time was the same as described for the
multiple time regression analysis.
Statistics
The linear regression line of each group in the kinetic
assays, whether Ki is significantly different from zero
(a condition of no influx), and the differences between
the regression lines in Ki and Vi were compared by
the least square method with GraphPad Prism software
(La Jolla, CA, USA).
Results
FGF19 is stable in both blood and brain
The degradation patterns of 125I-FGF19 in brain and
blood 10 min after iv delivery were determined by HPLC
(Figure 1). The retention time of intact 125I-FGF19 was
28 min, shown as a single peak in the chromatogram of
the injection solution. Acid precipitation of fraction #28
(96.75%) also confirmed that the peak represented intact
125I-FGF19. The 125I-FGF19 chromatogram of serum
was similar to that of the injection solution with only
one major peak, indicating that FGF19 was relatively
stable in serum for 10 min. However, there were three
peaks in the chromatogram of brain: at 5, 16, and
30 min. Further acid precipitation assay of these three
fractions (#5, #16, #30) showed that the precipitation
rates were 0.72%, 1.58%, and 92.59%, respectively. The
chromatogram of the brain processing control was
Figure 1 HPLC chromatogram of the degradation profiles of 125
I-FGF19 in brain and serum 10 min after iv injection. The first
fraction at the retention time of 5 min represents free 125I, the
second fraction at retention time of 16 min represents small
fragments of degraded 125I-FGF19, and the last fraction at retention
time 28–30 shows intact 125I-FGF19. Most radioactivity in the serum
coincided with that of the injection solution. The elution profile of
brain supernatant in mice 10 min after iv injection of 125I-FGF19 was
similar to that of ex-vivo processing (process control) where
125I-FGF19 was added in the homogenizer. The results indicate that
125I-FGF19 remained intact in the blood and brain compartments at
this time (n = 3 /group).
Figure 2 Acid precipitation rate of 125I-FGF19 and 131I-albumin
at 5, 10, and 20 min after iv delivery with or without the
presence of 56-fold excess unlabeled FGF19 (one mouse for
each time point). (A) In the brain, the acid precipitability of
125I-FGF19 was decreased at 10 and 20 min in comparison with the
5 min sample. The presence of excess unlabeled FGF19 helped to
maintain the high acid precipitability of 125I-FGF19 at 10 min but not
at 20 min. The acid precipitability of 131I-albumin remained high
throughout the study. (B) In serum, the decline of acid precipitability
of 125I-FGF19 was mainly seen at 20 min in the group receiving
excess unlabeled FGF19.
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curred ex-vivo during tissue processing. Analysis of the
area under the peak indicated that 10 min after iv de-
livery, 99.76% of the 125I-FGF19 remained intact in the
serum. Free 125I accounted for 0.04% of total ra-
dioactivity eluted whereas small degradation fragments
accounted for only 0.02%. In brain, 93.37% of the 125I-
FGF19 remained intact, even without normalization
with the processing control. Of the total radioactivity,
2.55% represented free 125I, where 3.35% were de-
graded fragments. 131I-albumin was relatively stable in
both brain and blood (data not shown).
Acid precipitation analysis is not as sensitive as HPLC,
but it offers a simple and fast way to check the integrity of
radioactively labeled small proteins. In brain, the acid pre-
cipitability of 125I-FGF19 decreased from 89.52% at 5 min
to 67.89% at 10 min after iv injection, and remained about
70% up to 20 min. The lower precipitability at 10 min
might be aberrant and it was lower than that seen by
HPLC. In the presence of 56-fold excess unlabeled FGF19
(the amount used was limited by cost), the precipitability
remained above 93% at 10 min, and decreased to 70% at
20 min after iv delivery (Figure 2A). In contrast with
the 125I-FGF19 in the brain, that in the serum was more
stable as shown by acid precipitability above 89% at
20 min. With excess unlabeled FGF19, the precipitability
of 125I-FGF19 in serum remained more than 98% at
10 min, and decreased to 76% at 20 min. The precipita-
bility of 131I-albmin either in brain or in serum was morethan 99% up to 20 min (Figure 2B). Both HPLC and acid
precipitation data indicate that FGF19 detected in serum
and in brain homogenate was stable, with detectable deg-
radation in the brain homogenate at 10 min, and that the
excess FGF19 slowed the degradation process.
Excess FGF19 extends the half-life of 125I-FGF19 in blood
As shown in Figure 3A, a two-phase exponential dis-
appearance model best fit the pattern of 125I-FGF19 in
the blood over a time course of 20 min. The half-time
disappearance of 125I-FGF19 was 0.90 min in the fast
phase and 9.2 min in the slow phase. Co-injection of 56-
fold excess unlabeled FGF19 decreased the fast phase
Figure 3 Multiple time-regression analysis of 125I-FGF19
transport from blood to brain. (A) The 125I-FGF19 clearance profile
in blood was fitted with a two-phase exponential disappearance
model. In the presence of 56-fold excess unlabeled FGF19, the area
under curve of 125I-FGF19 was increased and the half-life of the slow
phase of clearance was prolonged. (B) The influx rate Ki of 125I-FGF19
from blood to brain was not significant although the initial volume of
distribution Vi was significantly higher than that of the co-administered
vascular space marker 131I-albumin. The presence of excess unlabeled
FGF19 resulted in the influx of 125I-FGF19 (p = 0.05). The influx of
131I-albumin remained non-significant. Each time point indicates an
individual mouse (n = 8 /group).
Figure 4 In the in-situ brain perfusion study, there was
significant influx of 125I-FGF19 (values already normalized by
subtraction of 131I-albumin in the same mouse). Each data point
represents one mouse. The presence of 50-fold excess FGF19 or
FGF15 did not change the influx of 125I-FGF19.
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slow phase half-life to 143.5 min.
The influx of 125I-FGF19 from blood to brain is limited
and unmodified by excess FGF19
Determined by multiple-time regression analysis, the uni-
directional influx rate of 125I-FGF19 from blood to brain
was not significantly different from zero (Ki = 0.02 ±
0.14 μl/g-min; F1,6 = 0.03, p = 0.88). With co-administration
of 56-fold excess FGF19, the influx of 125I-FGF19 was bor-
derline significant (Ki = 0.11 ± 0.05 μl/g-min; F1,6 = 5.72,
p = 0.05). Although comparison of the influx rate of 125I-
FGF19 with and without the presence of excess FGF19 was
not significant (F1,12 = 0.32, p = 0.58), the linear correlationwas stronger (r = 0.7, in contrast to the “hot only” group
r = 0.07). This coincided with a greater area under curve
and longer half-life of the slow phase of 125I-FGF19 dis-
appearance in blood. Thus, in the presence of excess un-
labeled FGF19, more 125I-FGF19 was available to reach the
brain compartment. The initial volume of distribution of
125I-FGF19 (Vi = 15.75 ± 3.44 μl/g), though not decreased
significantly (F1,13 = 1.46, p = 0.25) by unlabeled FGF19
(Vi = 12.21 ± 0.21 μl/g), was significantly higher than that
of albumin (Vi = 9.98 ± 1.30 μl/g) (F1,13 = 5.6, p < 0.05).
Nonetheless, the influx rate of the vascular marker 131I-al-
bumin was not significantly different from either 0 or 125I-
FGF19 (Figure 3B).
The results from multiple-time regression analysis
after iv bolus injection of FGF19 may be affected by
serum binding proteins. Therefore, we further performed
in-situ brain perfusion with blood-free physiological
buffer. There was a significant influx of 125I-FGF19 from
perfusate to brain (Ki = 0.27 ± 0.06 μl/g-min, F1,8 =
22.06, p = 0.002). However, the presence of 50-fold
excess of either FGF19 or FGF15 did not change the
influx rate of 125I-FGF19. The Ki for 125I-FGF19 was
0.23 ± 0.04 μl/g-min in the presence of excess unlabeled
FGF19, and 0.33 ± 0.03 μl/g-min in the presence of
excess unlabeled FGF15. The slopes of these three
regression lines were not significantly different from
each other (F2,21 = 1.10, p = 0.35). Similarly, the excess
of FGF19 or FGF15 did not change the volume of distri-
bution of 125I-FGF19 (F2,23 = 0.24, p = 0.79) (Figure 4),
the values already being normalized by subtraction of
albumin space at each time point. The results suggest
that FGF19 had a low level of permeation across the
BBB in a process that is probably non-saturable, as the
amount of excess FGF19 or FGF15 used in this study
was not able to modulate the influx.
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also affected by excess FGF19
125I-FGF19 had an influx rate of 223.60 ± 55.47 μl/g-min
from blood to liver, significantly higher than zero (F1,5 =
16.26, p = 0.01). In the presence of excess unlabeled
FGF19, the Ki was reduced to 22.61 ± 3.82 μl/g-min, al-
though the influx remained significant compared with zero
(F1,6 = 34.96, p = 0.001). The difference in the liver uptake
of 125I-FGF19 between the two groups was significant
(F1,11 = 13.11, p = 0.004) (Figure 5A).
The influx of 125I-FGF19 to kidney showed large vari-
ation among data points, and there was no significant
linear regression (Ki = 7.78 ± 35.52 μl/g-min. F1,6 = 0.05,
p = 0.83). Contrary to the liver where co-injection of ex-
cess FGF19 inhibited the hepatic uptake of 125I-FGF19,
the kidney showed a greater influx of 125I-FGF19 in
the presence of 56-fold excess of unlabeled FGF19. The
Ki was 36.92 ± 11.89 μl/g-min (F1,6 = 9.65, p = 0.02)
(Figure 5B). The results suggest that FGF19 processingFigure 5 The influx of 125I-FGF19 from blood to peripheral
organs after iv injection. (A) In the liver, there was a rapid influx
of 125I-FGF19 (Ki = 223.60 ± 55.47 μl/g-min). The presence of 56-fold
excess unlabeled FGF19 produced a significant reduction of the Ki
which remained linear and higher than that of the vascular space
marker 131I-albumin. (B) In the kidney, the basal uptake of 125I-FGF19
was highly variable and not significantly different from zero. The
presence of excess unlabeled FGF19 resulted in a linear clearance of
125I-FGF19 but did not change the minimal uptake of 131I-albumin.
Each time point indicates an individual mouse (n = 8/group).by the liver and kidney is dependent on the amount of
FGF19 available in blood.
Discussion
We first showed that human FGF19 was stable in mouse
blood and its half-time disappearance was further ex-
tended by excess FGF19. In the “hot only” group, there
was no meaningful permeation of 125I-FGF19 into brain
as seen by multiple-time regression analysis. The initial
volume of distribution of 125I-FGF19 remained higher
than that of co-administered 131I-albumin. The presence
of FGF19 in the cerebral vasculature may allow its bind-
ing and activation of BBB endothelia and thus induce
CNS function indirectly without crossing the BBB, as
seen with adiponectin [19]. Nevertheless, the small por-
tion of FGF19 entering the brain was stable for at least
10 min, so that it could exert direct CNS effects.
The influx of 125I-FGF19 became significant in the
presence of excess unlabeled FGF19 or its homolog
FGF15 both by multiple-time regression analysis after iv
injection and by in-situ brain perfusion. Because of the
low level of permeation without an increase of Vi over
time, we did not perform capillary depletion to further
determine the compartmental distribution of FGF19
loosely adherent to microvessels, entrapped in endothe-
lia, or already transcytosed across the BBB to reach brain
parenchyma. However, based on the linearity of brain
uptake over time, we expect that a significant amount of
125I-FGF19 reached brain parenchyma in the group re-
ceiving excess unlabeled FGF19. Differences between the
iv and in-situ brain perfusion studies were probably
caused by blood-borne factors and differential tissue dis-
tribution. Indeed, the serum half-life of 125I-FGF19 was
increased by the presence of excess unlabeled FGF19,
particularly during the slow phase of distribution. This
coincided with a larger area under curve of 125I-FGF19,
suggesting that more 125I-FGF19 was available to reach
the brain compartment. This probably occurred at least
partially from the excess unlabeled FGF19 saturating
peripheral uptake or degradation processes.
To determine a possible effect of peripheral tissue dis-
tribution of FGF19 entry into brain, we determined its
uptake by liver and kidney. There was a high influx rate
of FGF19 from blood to liver, consistent with the liver
being a major target organ for FGF15/19 [4,20,21]. In
the presence of excess unlabeled FGF19, the influx rate
of FGF19 to the liver was significantly attenuated. This
suggests the presence of a specific, saturable process.
Uptake of FGF19 by the liver may be mediated by both
conduit capillaries (reflected by albumin space) and ex-
change capillaries; the latter probably represent the frac-
tion attenuated by excess unlabeled FGF19. Receptors
for FGF15/19 include FGF receptors (particularly R4)
and α- and β-Klotho proteins [22,23]. The expression
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the most probable mediators of regulated liver uptake
of 125I-FGF19 in this study.
β-Klotho plays an important role in regulating tran-
sient receptor potential vanilloid 5 (TRPV5) in the
kidneys [25]. The kidney is clearly involved in the clear-
ance of FGF19, as blood concentrations of FGF19 are
higher in subjects with end stage renal disease [26].
However, the influx rate of FGF19 to the kidney of nor-
mal healthy mice was non-linear during the study period
of 1–20 min. Although there have not been comparative
studies, differences in the level of expression of these
FGF15/19 binding proteins in the liver and kidney might
underlie the difference in the organ-specific influx rate.
The saturation of FGF receptors and Klotho in the liver
by excess unlabeled FGF19 could have reduced the
influx of 125I-FGF19, whereas the simultaneous displace-
ment and increased blood concentration of 125I-FGF19
may enable a linear renal excretion.
The low permeability of FGF19 across the BBB con-
trasts with that of FGF21, which shows significant influx
by simple diffusion across the BBB [14]. FGF15/19 and
FGF21 belong to the class of endocrine FGF small pro-
teins, as their weak interaction with heparin sulfate en-
ables them to diffuse away from the site of production.
However, unlike FGF21 that is mainly secreted from the
liver after prolonged fasting to exert glucagon-like ef-
fects, FGF15/19 is produced by the small intestine in re-
sponse to feeding and shows insulin-like actions [21,27].
We do not anticipate a major difference of BBB interac-
tions between the homologous proteins FGF15 and
FGF19 that show 53% structural identity [2]; this is sup-
ported by the lack of effect of excess unlabeled FGF15 to
modulate the influx of 125I-FGF19.
Although only a trace amount of 125I-FGF19 was used in
this study, the concentration remains higher than that of
endogenous FGF15 in mice or FGF19 in humans. Thus,
peripheral actions of FGF15/19 in metabolic regulation
may dominate over CNS effects in the basal state. It is not
clear whether peripheral FGF15/19 plays a prominent role
to induce CNS effects in metabolic signaling and obesity
[6]. However, the initial volume of distribution, Vi, of 125I-
FGF19 was higher than that of 131I-albumin, supporting
the possibility that FGF19 modifies BBB endothelial func-
tion. There are also developmental changes of FGF19 gene
expression in brain microvessels collected from 2-month-
old to 8-year-old humans [28]. Though it is not clear
whether these transcripts are translated, and though adult
brain does not express FGF19 [29], it is apparent that
FGF19 can affect CNS function on either side of the BBB.
Conclusion
In summary, we showed in normal mice that 125I-FGF19
remained stable in blood and brain homogenate at leastfor 10 min. It did not have significant entry into brain
after iv injection, but there was increased permeation in
the presence of excess unlabeled FGF19 and during
in-situ brain perfusion. In the presence of excess FGF19,
the first rapid phase clearance of 125I-FGF19 in serum
was shortened and the second slow phase was remark-
ably prolonged. 125I-FGF19 had a fast uptake by the liver,
and this was significantly attenuated by excess FGF19. In
the presence of excess FGF19, the low level of kidney
excretion of 125I-FGF19 showed a linear acceleration.
Thus, the pharmacokinetics of FGF19 entry into brain is
influenced by its serum concentration, and shows signifi-
cant hepatic and renal interactions.
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